Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Error in Author Name Tagging

Error in Author Name Tagging Letters 1. Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL. Author Affiliations: SWOG Statistical Center, Fred Hutchinson Cancer Research The scientific impact of positive and negative phase 3 cancer clinical trials Center, Seattle, Washington (Unger, Barlow); Columbia University, New York, [published online March 10, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2015.6487. New York (Hershman). 2. Quinn DI, Tangen CM, Hussain M, et al. Docetaxel and atrasentan versus Corresponding Author: Joseph M. Unger, PhD, SWOG Statistical Center, docetaxel and placebo for men with advanced castration-resistant prostate Fred Hutchinson Cancer Research Center, 1100 N Fairview Ave, M3-C102, cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013;14(9): PO Box 19024, Seattle, WA 98109 (junger@fredhutch.org). 893-900. Published Online: June 23, 2016. doi:10.1001/jamaoncol.2016.1772. 3. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin Conflict of Interest Disclosures: None reported. compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: 1. Graham R, Mancher M, Wolman DM, et al; Committee on Standards for clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27 Developing Trustworthy Clinical Practice Guidelines. Board on Health Care (15):2530-2535. Services: Clinical Practice Guidelines We Can Trust. Washington, DC: National 4. Rudin CM, Ismaila N, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Error in Author Name Tagging

JAMA Oncology , Volume 2 (11) – Nov 29, 2016

Error in Author Name Tagging

Abstract

Letters 1. Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL. Author Affiliations: SWOG Statistical Center, Fred Hutchinson Cancer Research The scientific impact of positive and negative phase 3 cancer clinical trials Center, Seattle, Washington (Unger, Barlow); Columbia University, New York, [published online March 10, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2015.6487. New York (Hershman). 2. Quinn DI, Tangen CM, Hussain M, et al. Docetaxel and atrasentan versus...
Loading next page...
 
/lp/american-medical-association/error-in-author-name-tagging-YH9z3e300i

References (8)

Publisher
American Medical Association
Copyright
Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2016.4564
pmid
27685853
Publisher site
See Article on Publisher Site

Abstract

Letters 1. Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL. Author Affiliations: SWOG Statistical Center, Fred Hutchinson Cancer Research The scientific impact of positive and negative phase 3 cancer clinical trials Center, Seattle, Washington (Unger, Barlow); Columbia University, New York, [published online March 10, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2015.6487. New York (Hershman). 2. Quinn DI, Tangen CM, Hussain M, et al. Docetaxel and atrasentan versus Corresponding Author: Joseph M. Unger, PhD, SWOG Statistical Center, docetaxel and placebo for men with advanced castration-resistant prostate Fred Hutchinson Cancer Research Center, 1100 N Fairview Ave, M3-C102, cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013;14(9): PO Box 19024, Seattle, WA 98109 (junger@fredhutch.org). 893-900. Published Online: June 23, 2016. doi:10.1001/jamaoncol.2016.1772. 3. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin Conflict of Interest Disclosures: None reported. compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: 1. Graham R, Mancher M, Wolman DM, et al; Committee on Standards for clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27 Developing Trustworthy Clinical Practice Guidelines. Board on Health Care (15):2530-2535. Services: Clinical Practice Guidelines We Can Trust. Washington, DC: National 4. Rudin CM, Ismaila N,

Journal

JAMA OncologyAmerican Medical Association

Published: Nov 29, 2016

There are no references for this article.